Compare ATLC & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLC | AGMB |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | Belgium |
| Employees | 576 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.4M | 677.9M |
| IPO Year | N/A | N/A |
| Metric | ATLC | AGMB |
|---|---|---|
| Price | $66.43 | $10.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $90.00 | $32.00 |
| AVG Volume (30 Days) | 53.3K | ★ 162.1K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $477.21 | N/A |
| Revenue Next Year | $10.42 | $33.33 |
| P/E Ratio | $9.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.74 | $9.00 |
| 52 Week High | $78.91 | $17.45 |
| Indicator | ATLC | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 73.16 | 40.38 |
| Support Level | $64.75 | $10.07 |
| Resistance Level | $70.95 | $12.81 |
| Average True Range (ATR) | 2.80 | 1.57 |
| MACD | 1.49 | -0.00 |
| Stochastic Oscillator | 96.72 | 32.24 |
Atlanticus Holdings Corp is a financial technology company powering more inclusive financial solutions for Everyday Americans. It provides technology and other support services to lenders who offer an array of financial products and services to consumers. The company's products and services are reported through two reportable segments. Credit as a Service (CaaS) offers products including private label credit cards using the Fortiva and Curae brand names as well as merchant-associated brands and Auto Finance provides purchase and/or service loans secured by automobiles from or for, and also provides floor-plan financing for, a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here used car business.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.